91麻豆精品国产综合久久久,人人玩人人添人人澡超碰,五月婷婷六月激情综合,国产一级二级三级久久

訂購(gòu)信息
上海拜力生物科技公司
Tel:400-968-7988    021-33779008
TAK-875(Fasiglifam),GPR40Agonist
品牌:Xcessbio
貨號(hào):M60220-2s
規(guī)格:2 mg solid
貨期:
應(yīng)用: 點(diǎn)擊這里給我發(fā)消息  咨詢客服

TAK-875(Fasiglifam),GPR40Agonist

商品詳情 參考文獻(xiàn) 相關(guān)資料
Product Information
Molecular Weight: 533.63
Formula: C29H32O7S.1/2H2O
Purity: ≥98%
CAS#: 1374598-80-7
Solubility: DMSO up to 100 mM
Chemical Name: (S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable partial GPR40 agonist with an EC50 ~14 nM. ?It has binding affinity to the human GPR40 receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK-875 has no agonist potency to other members of the FFA receptor family with EC50 >10 μM. The 2.3 ? resolution co-complex structure of hGPR40-TAK-875 reveals a unique binding mode of TAK-875 and suggests that entry to the non-canonical binding pocket most probably occurs via the lipid bilayer. Consistent with the activation of the Gqα-mediated signaling pathway, TAK-875 augments glucose-dependent insulin secretion in pancreatic β cells. Prolonged stimulation of GPR40/FFA1 by TAK-875 does not cause pancreatic β Cell dysfunction or induction of apoptosis. Termination phase III development of TAK-875 (Fasiglifam) for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.


How to Use:

  • In vitro:? TAK-875 was used at 1 μM final concentration in various in vitro assays.
  • In vivo: TAK-875 was dosed to female Wistar fatty rats subjected to oral glucose tolerance test via oral gavage at 3 mg/kg one hour before an oral glucose challenge. Formulation is 0.5% CMC/0.25% Tween 80 in water. In type 2 diabetic N-STZ-1.5 rats, administration of TAK-875 (1-10 mg/kg PO) shows a clear improvement in glucose tolerance and augments insulin secretion. TAK-875 (10 mg/kg, PO) significantly augments plasma insulin levels and reduces fasting hyperglycemia in male Zucker diabetic fatty rats.?


Reference:?

  1. 1.????? Negoro N, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. (2010) ACS Med Chem Lett. 1(6):290-4.
  2. 2.????? Tsujihata Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (2011) J Pharmacol Exp Ther. 339(1):228-37.
  3. 3.????? Srivastava A, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. (2014) Nature. 513(7516):124-7.?

? ??
? ??


Products are for research use only. Not for human use.

?

熱銷產(chǎn)品
熱銷產(chǎn)品排行榜
  • 關(guān)于我們
  • 購(gòu)物流程
  • 支付方式
  • 配送方式

請(qǐng)打開(kāi)QQ掃碼聯(lián)系
Copyright@ 2003-2024  進(jìn)口試劑采購(gòu)網(wǎng)版權(quán)所有     

BIOLEAF熱搜   BIOLEAF試劑盒   BIOLEAF ELISA   BIOLEAF試劑   BIOLEAF品牌   BIOLEAF抗體   BIOLEAF耗材   BIOLEAF小儀器

sitemap   細(xì)胞庫(kù)查詢   危險(xiǎn)品圖標(biāo)

本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研!

         滬ICP備08023583號(hào)-6     
產(chǎn)品咨詢
QQ掃碼溝通
在線客服
服務(wù)電話
400-968-7988
掃碼關(guān)注
微信公眾號(hào)二維碼

滬公網(wǎng)安備 31011202007338號(hào)

韶关市| 南充市| 阿拉善右旗| 庆云县| 锡林郭勒盟| 富阳市| 惠来县| 石泉县| 涪陵区| 金溪县| 鄂托克前旗| 塘沽区| 巩义市| 克东县| 秦安县| 东丽区| 鸡西市| 五台县| 吉安市| 杭州市| 涞水县| 龙门县| 阳山县| 永丰县| 中阳县| 邛崃市| 仁怀市| 广丰县| 日土县| 五台县| 桂平市| 宜昌市| 长葛市| 淄博市| 博罗县| 祁东县| 渝中区| 马山县| 库尔勒市| 清河县| 民乐县|